Clinical Ink has developed a unique offering — the electronic Lupus Assessment Suite (eLAS®) to address fundamental challenges impacting systemic lupus erythematosus (SLE) studies and the integrity of the study endpoints.
eLAS is a therapeutic-specific application of Clinical Ink’s Lunexis™. Unlike other applications that simply offer stand-alone electronic versions of questionnaires, eLAS features a fully integrated suite of SLE disease assessment questionnaires, physical assessment, tender/swollen joint count, PGA, and summary forms.
